Heideman DA - Search Results

1

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF. Kuiper JL, et al. Among authors: heideman da. Lung Cancer. 2014 Jul;85(1):19-24. doi: 10.1016/j.lungcan.2014.03.016. Epub 2014 Mar 23. Lung Cancer. 2014. PMID: 24768581

2

A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations.

Kramer D, Thunnissen FB, Gallegos-Ruiz MI, Smit EF, Postmus PE, Meijer CJ, Snijders PJ, Heideman DA. Kramer D, et al. Among authors: heideman da. Cell Oncol. 2009;31(3):161-7. doi: 10.3233/CLO-2009-0466. Cell Oncol. 2009. PMID: 19478384 Free PMC article.

3

A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes.

Heideman DA, Thunnissen FB, Doeleman M, Kramer D, Verheul HM, Smit EF, Postmus PE, Meijer CJ, Meijer GA, Snijders PJ. Heideman DA, et al. Cell Oncol. 2009;31(5):329-33. doi: 10.3233/CLO-2009-0489. Cell Oncol. 2009. PMID: 19759413 Free PMC article.

4

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.

Becker A, Crombag L, Heideman DA, Thunnissen FB, van Wijk AW, Postmus PE, Smit EF. Becker A, et al. Among authors: heideman da. Eur J Cancer. 2011 Nov;47(17):2603-6. doi: 10.1016/j.ejca.2011.06.046. Epub 2011 Jul 23. Eur J Cancer. 2011. PMID: 21784628

5

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study.

van Grieken NC, Aoyama T, Chambers PA, Bottomley D, Ward LC, Inam I, Buffart TE, Das K, Lim T, Pang B, Zhang SL, Tan IB, Carvalho B, Heideman DA, Miyagi Y, Kameda Y, Arai T, Meijer GA, Tsuburaya A, Tan P, Yoshikawa T, Grabsch HI. van Grieken NC, et al. Among authors: heideman da. Br J Cancer. 2013 Apr 16;108(7):1495-501. doi: 10.1038/bjc.2013.109. Epub 2013 Mar 19. Br J Cancer. 2013. PMID: 23511561 Free PMC article.

6

EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?

Hendriks LE, Smit EF, Vosse BA, Mellema WW, Heideman DA, Bootsma GP, Westenend M, Pitz C, de Vries GJ, Houben R, Grünberg K, Bendek M, Speel EJ, Dingemans AM. Hendriks LE, et al. Among authors: heideman da. Lung Cancer. 2014 Apr;84(1):86-91. doi: 10.1016/j.lungcan.2014.01.006. Epub 2014 Jan 23. Lung Cancer. 2014. PMID: 24529684

7

High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.

Kuiper JL, Heideman DA, Thunnissen E, van Wijk AW, Postmus PE, Smit EF. Kuiper JL, et al. Among authors: heideman da. Eur J Cancer. 2014 May;50(7):1399-401. doi: 10.1016/j.ejca.2014.02.005. Epub 2014 Feb 28. Eur J Cancer. 2014. PMID: 24582911 No abstract available.

8

DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach.

Hubers AJ, Heideman DA, Burgers SA, Herder GJ, Sterk PJ, Rhodius RJ, Smit HJ, Krouwels F, Welling A, Witte BI, Duin S, Koning R, Comans EF, Steenbergen RD, Postmus PE, Meijer GA, Snijders PJ, Smit EF, Thunnissen E. Hubers AJ, et al. Among authors: heideman da. Br J Cancer. 2015 Mar 17;112(6):1105-13. doi: 10.1038/bjc.2014.636. Br J Cancer. 2015. PMID: 25719833 Free PMC article.

9

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.

Kuiper JL, Hashemi SM, Thunnissen E, Snijders PJ, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman DA, Smit EF. Kuiper JL, et al. Among authors: heideman da. Br J Cancer. 2016 Dec 6;115(12):1504-1512. doi: 10.1038/bjc.2016.372. Epub 2016 Nov 22. Br J Cancer. 2016. PMID: 27875527 Free PMC article.

10

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM. van der Wekken AJ, et al. PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017. PLoS One. 2017. PMID: 28854272 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

229 results

Search Page

Filters